Kadowaki Takashi, Lee Sang Yeoup, Ogawa Wataru, Nishida Tomoyuki, Overvad Maria, Tobe Kazuyuki, Yamauchi Toshimasa, Lim Soo
Toranomon Hospital, Tokyo, Japan.
Family Medicine Clinic and Biomedical Research Institute, Pusan National University Yangsan Hospital, Yangsan, South Korea; Department of Medical Education, Pusan National University School of Medicine, Yangsan, South Korea.
Obes Res Clin Pract. 2024 Nov-Dec;18(6):457-464. doi: 10.1016/j.orcp.2025.01.002. Epub 2025 Jan 16.
To explore the effects of semaglutide versus placebo on body weight (BW) by subgroups of baseline characteristics.
In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks. A subset of Japanese participants with type 2 diabetes (T2D) was also included. In this post-hoc analysis, change from baseline in BW (%) was assessed by subgroups of baseline characteristics including baseline BW, body mass index, age, sex, glycemic status, dyslipidemia, and hypertension.
Of 401 participants (148 female and 253 male) included, the estimated mean change in BW was clinically relevant across all subgroups for semaglutide 2.4 mg, ranging from -9.40 % to -16.42 %. Estimated treatment differences also favored both semaglutide doses versus placebo. Significant treatment-by-subgroup interactions were observed for sex with semaglutide 1.7 mg and 2.4 mg versus placebo at week 68 (p = 0.0008 and p = 0.0005, respectively). Significant treatment-by-subgroup interactions were also observed for presence of T2D and dyslipidemia at baseline, for semaglutide 2.4 mg versus placebo only (p = 0.0381 and p = 0.0181, respectively).
Semaglutide reduces BW in a wide demographic of people with a range of weight-related comorbidities in an East Asian population.
按基线特征亚组探讨司美格鲁肽与安慰剂对体重（BW）的影响。
在STEP 6研究中，将超重或肥胖的日本和韩国成年人随机分为皮下注射司美格鲁肽2.4mg组、司美格鲁肽1.7mg组或安慰剂组，治疗68周。还纳入了一部分患有2型糖尿病（T2D）的日本参与者。在这项事后分析中，通过基线特征亚组评估体重相对于基线的变化百分比（%），这些基线特征包括基线体重、体重指数、年龄、性别、血糖状态、血脂异常和高血压。
在纳入的401名参与者（148名女性和253名男性）中，司美格鲁肽2.4mg在所有亚组中的估计平均体重变化均具有临床意义，范围为-9.40%至-16.42%。估计的治疗差异也显示司美格鲁肽两个剂量组均优于安慰剂组。在第68周时，观察到司美格鲁肽1. July 2023 mg和2.4mg与安慰剂相比，在性别方面存在显著的治疗×亚组交互作用（分别为p = 0.0008和p = 0.0005）。对于基线时存在T2D和血脂异常的情况，仅观察到司美格鲁肽2.4mg与安慰剂相比存在显著的治疗×亚组交互作用（分别为p = 0.0381和p = 0.0181）。
在东亚人群中，司美格鲁肽可降低广泛人群的体重，这些人群存在一系列与体重相关的合并症。
